🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Kidney Transplant Failure and Rejection

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant NCT07508787Phase 214 sites📍 Sacramento📍 Tampa📍 Atlanta Nefro Avillion Clinical Development, LLC · Tests: Siplizumab, Rabbit anti-thymocyte globulin Tacrolimus Pharmacokinetic Subpopulations NCT04526431n/a2 sites📍 Grenoble📍 Saint-Etienne University Hospital, Grenoble · Tests: Dosage Forms Oral A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients NCT05325008Phase 313 sites📍 Canberra📍 New Lambton Heights📍 Randwick The University of Queensland · Tests: Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection NCT05084768n/a1 site📍 Loma Linda Loma Linda University · Tests: Donor-derived cell-free DNA REgulatory T Cell Therapy to Achieve Immunosuppression REduction NCT06552169Phase 27 sites📍 Phoenix📍 Chicago📍 Rochester Singulera Therapeutics Inc. · Tests: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk NCT07053462Phase 1, Phase 21 site📍 Beijing AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC · Tests: Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection NCT03955172NA1 site📍 Lyon Hospices Civils de Lyon · Tests: Everolimus Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants NCT05525507Phase 11 site📍 Los Angeles University of California, Los Angeles · Tests: Conditioning and Stem cell infusion Empagliflozin Treatment in Kidney Transplant Recipients NCT06013865Phase 45 sites📍 Hines📍 Iowa City📍 Omaha VA Office of Research and Development · Tests: Empagliflozin Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant NCT05027906Phase 1, Phase 29 sites📍 Cincinnati📍 Camperdown📍 Adelaide Eledon Pharmaceuticals · Tests: AT-1501 TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation NCT06801262n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure NCT06676696Phase 41 site📍 Barcelona Hospital Universitari Vall d'Hebron Research Institute · Tests: Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy